Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Chemicals maker Lanxess to sell its shares in Envalior in 2026
    Finance

    Chemicals maker Lanxess to sell its shares in Envalior in 2026

    Published by Global Banking & Finance Review®

    Posted on September 23, 2025

    2 min read

    Last updated: January 21, 2026

    Chemicals maker Lanxess to sell its shares in Envalior in 2026 - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:equityinvestmentfinancial markets

    Quick Summary

    Lanxess aims to sell its 40.94% stake in Envalior by 2026, with a base price of 1.2 billion euros. Share price adjustments depend on Envalior's EBITDA.

    Table of Contents

    • Lanxess Stake Sale Overview
    • Details of the Share Sale
    • Impact on Lanxess Shares
    • Purchase Price Adjustments

    Lanxess Plans to Divest Its 40.94% Stake in Envalior by 2026

    Lanxess Stake Sale Overview

    (Reuters) -Specialty chemicals maker Lanxess will offer to sell all of its 40.94% stake in Envalior to its joint venture partner, an investment company of Advent International, it said on Tuesday.

    Lanxess said in a statement it had agreed to a base purchase price of around 1.2 billion euros ($1.42 billion) for the tendered shares.

    "If and to what extent the share sale will be completed will be known by March 2026 at the latest," the company said.

    Details of the Share Sale

    Shares in Lanxess jumped 8.5% as of 1242 GMT, topping the Germany's mid-cap index, and on target for their best day since March.

    Impact on Lanxess Shares

    Potential adjustments to the purchase price may only arise from the development of Envalior's earnings before interest, taxes, depreciation and amortisation, it said.

    The purchase price will increase, if the EBITDA in the 12 months to April 1, 2026, exceeds the core profit used as the basis for the valuation of the joint venture prior to the time of its incorporation.

    Purchase Price Adjustments

    If the current EBITDA falls below the historical EBITDA by more than 10%, the price will be reduced pro rata.

    "Envalior's debt is not taken into account for the determination of the purchase price for the tendered shares," the chemicals group added.

    ($1 = 0.8478 euros)

    (Reporting by Ozan Ergenay in Gdansk, Editing by Rachel More and Barbara Lewis)

    Key Takeaways

    • •Lanxess plans to sell its 40.94% stake in Envalior.
    • •The sale is expected to be completed by March 2026.
    • •Base purchase price set at 1.2 billion euros.
    • •Price adjustments depend on Envalior's EBITDA.
    • •Lanxess shares rose 8.5% following the announcement.

    Frequently Asked Questions about Chemicals maker Lanxess to sell its shares in Envalior in 2026

    1What is equity?

    Equity refers to the ownership interest in a company, represented by shares of stock. It signifies the value of an ownership stake in a business.

    2What is a stake sale?

    A stake sale involves selling a portion of ownership in a company, typically represented by shares. It can be part of strategic financial decisions.

    3What is EBITDA?

    EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure used to analyze a company's operating performance.

    4What is a purchase price adjustment?

    A purchase price adjustment is a change in the agreed purchase price of an asset based on specific performance metrics or conditions.

    5What is a joint venture?

    A joint venture is a business arrangement where two or more parties agree to pool their resources for a specific project or business activity.

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostBoE hawk Pill says he is more comfortable on inflation risk
    Next Finance PostIreland's Kingspan plans Amsterdam IPO for data-centre focused unit